Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

Takashi Ishida, Tatsuro Joh, Naokuni Uike, +17

Journal of Clinical Oncology

Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin

Theodor W. Schulte, Shiro Akinaga, Shiro Soga, +4

Cell Stress and Chaperones

MedicineN-terminal DomainMolecular BiologyAntibiotic Radicicol BindsPharmacology +3

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Michinori Ogura, Takashi Ishida, Kiyohiko Hatake, +16

Journal of Clinical Oncology

Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma

Kazuhito Yamamoto, Atae Utsunomiya, Kensei Tobinai, +17

Journal of Clinical Oncology

Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.

Rochelle Bagatell, Gillian Paine-Murrieta, Charles W. Taylor, +4

PubMed

ApoptosisCell DeathCytotoxic ActivityAntitumor Antibiotics GeldanamycinHsp90-binding Agents +15

Identification of Ras farnesyltransferase inhibitors by microbial screening.

Masatake Hara, Koji Akasaka, Shiro Akinaga, +6

Proceedings of the National Academy of Sciences

Medicinal ChemistryRas Farnesyltransferase InhibitorsGpa1 DisruptionBiochemistryMedicine +10

Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase <scp>II</scp> study

Takashi Ishida, Tatsuro Jo, Shigeki Takemoto, +18

British Journal of Haematology

Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

Toshihiko Ishii, Takashi Ishida, Atae Utsunomiya, +9

Clinical Cancer Research

A novel telomerase template antagonist (GRN163) as a potential anticancer agent.

Akira Asai, Yuko Oshima, Yoshihiro Yamamoto, +12

PubMed

PathologyInitial Telomere LengthPharmacotherapyTumor BiologyMolecular Pharmacology +17

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Eiichi Fuse, Hiromi Tanii, Noriaki Kurata, +14

PubMed

Molecular PharmacologyAlpha1-acid GlycoproteinUnusual PharmacokineticsOncologyGlycosylation +12